TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02451670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prioritized Clinical Decision Support
Description: After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
Study: NCT03229993

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT
Description: OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
Study: NCT02110758

Intervention type: OTHER
Intervention: Pilot of Patient-Centered Oncology Care
Description: Patient-Centered Oncology Care addresses six domains: track \& coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track \& coordinate care, and measure and improve performance.

Intervention type: OTHER
Intervention: Pilot of Patient-Centered Oncology Care
Description: Patient-Centered Oncology Care addresses six domains: track \& coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track \& coordinate care, and measure and improve performance.

Intervention type: OTHER
Intervention: Pilot of Patient-Centered Oncology Care
Description: Patient-Centered Oncology Care addresses six domains: track \& coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track \& coordinate care, and measure and improve performance.
Study: NCT04084951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-PBMC-HPV
Description: antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-PBMC-HPV
Description: antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-PBMC-HPV
Description: antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: programmed cell death ligand 1 (PD-L1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: programmed cell death 1 (PD-1) blocking antibody
Study: NCT02755103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention (MBRP)
Description: MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
Study: NCT03989128

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo medical chart review

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT04104503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Description: Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Lu AF11167
Description: single iv microdose administered as a 15 minutes infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Lu AF11167
Description: single iv microdose administered as a 15 minutes infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Lu AF11167
Description: single iv microdose administered as a 15 minutes infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)
Description: Single oral dose
Study: NCT05468294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2
Description: F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab, fixed dose
Description: Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
Study: NCT02097329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib commercial free base
Description: 125 mg oral capsule single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: 20 mg oral tablet 10 hours before and 2 hours after palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib commercial free base
Description: 125 mg oral capsule single dose
Study: NCT03535493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
Study: NCT02097329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antacid
Description: 30 mL orally once (2h before palbociclib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antacid
Description: 30 mL orally once (2h after palbociclib)
Study: NCT01706341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administer acetate Ringer's solution
Description: During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administer acetate Ringer's solution
Description: During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetate Ringer's solution containing no glucose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetate Ringer's solution containing 1% glucose
Study: NCT01129063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Pharmaceutical form : tablet~Route of administration: oral
Study: NCT02791919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO
Study: NCT02114424

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positional vibrator belt
Description: Belt with vibarator to avoid sleep supine
Study: NCT02259374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK 0.2% ROPIVACAINE
Description: Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK 0.2% ROPIVACAINE
Description: Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK 0.4% ROPIVACAINE
Description: Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK 0.4% ROPIVACAINE
Description: Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
Study: NCT01567774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: os, 20 mg, once per day, for 30 days
Study: NCT01735045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens
Description: Daily Wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens
Study: NCT03535493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Float REST
Description: A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT + Float REST
Description: The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
Study: NCT01047306

Intervention type: OTHER
Intervention: assessment
Description: Physical, developmental, neurological, behavioral, and neurocognitive assessments
Study: NCT02974374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: Single or repeated, escalating dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or repeated, escalating dose
Study: NCT00586300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training program
Description: The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management training program
Description: The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training and self-management training programs
Description: This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2.
Study: NCT00618397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
Study: NCT02854566

Intervention type: DEVICE
Intervention: osteosynthesis
Description: Fracture reduction and fixation with screws/plates/cables (standard of care)
Study: NCT03657199

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac computed tomography
Description: Routine computed tomography of the heart before discharge

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac computed tomography
Description: Routine computed tomography of the heart before discharge
Study: NCT03551678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active feedback gait retraining
Description: The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
Study: NCT02175966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2a

Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon α-2a
Study: NCT01696864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand tutor rehabilitation device
Description: A rehabilitation device for the hand

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm tutor rehabilitation device
Description: A rehabilitation device for the arm
Study: NCT03111979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04053478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine in solution, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine in solution, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine in solution, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin, at applicable concentrations based on literature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin, at applicable concentrations based on literature
Study: NCT00583869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
Study: NCT02189616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: send weekly mobile phone short message reminders to the intervention group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: send weekly mobile phone short message reminders to the intervention group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS consultation
Description: told patients to consult qualified asthma nurses by SMS when they need

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular care
Description: patients are asked to fill in their paper asthma diary daily for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular care
Description: patients are asked to fill in their paper asthma diary daily for 3 months

Intervention type: OTHER
Group type: OTHER
Intervention: regular care
Description: patients are asked to fill in their paper asthma diary daily for 3 months
Study: NCT00878345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine sedation protocol
Description: Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentobarbital sedation protocol
Description: Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation.
Study: NCT03387410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous IRDye 800BK
Description: Fluorescence of the ureter using IRDye 800BK
Study: NCT02042690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haplo-identical HSCT
Description: Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
Study: NCT02218359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Fosfomycin Inhalation Solution
Description: 300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized placebo
Description: Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amikacin Fosfomycin Inhalation Solution
Description: Open-label crossover for all patients Days 6-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Fosfomycin Inhalation Solution
Description: Open-label crossover for all patients Days 6-10